321 related articles for article (PubMed ID: 17206462)
1. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.
Vedder AC; Linthorst GE; van Breemen MJ; Groener JE; Bemelman FJ; Strijland A; Mannens MM; Aerts JM; Hollak CE
J Inherit Metab Dis; 2007 Feb; 30(1):68-78. PubMed ID: 17206462
[TBL] [Abstract][Full Text] [Related]
2. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women.
Gupta S; Ries M; Kotsopoulos S; Schiffmann R
Medicine (Baltimore); 2005 Sep; 84(5):261-268. PubMed ID: 16148726
[TBL] [Abstract][Full Text] [Related]
3. Early therapeutic intervention in females with Fabry disease?
Hughes DA
Acta Paediatr; 2008 Apr; 97(457):41-7. PubMed ID: 18339187
[TBL] [Abstract][Full Text] [Related]
4. Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation.
Lavalle L; Thomas AS; Beaton B; Ebrahim H; Reed M; Ramaswami U; Elliott P; Mehta AB; Hughes DA
PLoS One; 2018; 13(4):e0193550. PubMed ID: 29621274
[TBL] [Abstract][Full Text] [Related]
5. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
6. Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.
Wijburg FA; Bénichou B; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini C; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymańska A; Ramaswami U
PLoS One; 2015; 10(5):e0124987. PubMed ID: 25955246
[TBL] [Abstract][Full Text] [Related]
7. Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy.
Gaggl M; Lajic N; Heinze G; Voigtländer T; Sunder-Plassmann R; Paschke E; Fauler G; Sunder-Plassmann G; Mundigler G
Int J Med Sci; 2016; 13(5):340-6. PubMed ID: 27226774
[TBL] [Abstract][Full Text] [Related]
8. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.
Auray-Blais C; Blais CM; Ramaswami U; Boutin M; Germain DP; Dyack S; Bodamer O; Pintos-Morell G; Clarke JT; Bichet DG; Warnock DG; Echevarria L; West ML; Lavoie P
Clin Chim Acta; 2015 Jan; 438():195-204. PubMed ID: 25149322
[TBL] [Abstract][Full Text] [Related]
9. Investigation of correlation of urinary globotriaosylceramide (Gb3) levels with markers of renal function in patients with Fabry disease.
Moura AP; Hammerschmidt T; Deon M; Giugliani R; Vargas CR
Clin Chim Acta; 2018 Mar; 478():62-67. PubMed ID: 29274327
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of patients with Fabry disease in Argentina].
AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
[TBL] [Abstract][Full Text] [Related]
11. Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS/MS in Urine of Fabry Disease Patients.
Boutin M; Menkovic I; Martineau T; Vaillancourt-Lavigueur V; Toupin A; Auray-Blais C
Anal Chem; 2017 Dec; 89(24):13382-13390. PubMed ID: 29099167
[TBL] [Abstract][Full Text] [Related]
12. Risk of death in heart disease is associated with elevated urinary globotriaosylceramide.
Schiffmann R; Forni S; Swift C; Brignol N; Wu X; Lockhart DJ; Blankenship D; Wang X; Grayburn PA; Taylor MR; Lowes BD; Fuller M; Benjamin ER; Sweetman L
J Am Heart Assoc; 2014 Feb; 3(1):e000394. PubMed ID: 24496231
[TBL] [Abstract][Full Text] [Related]
13. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
[TBL] [Abstract][Full Text] [Related]
14. Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry.
Lavoie P; Boutin M; Auray-Blais C
Anal Chem; 2013 Feb; 85(3):1743-52. PubMed ID: 23248976
[TBL] [Abstract][Full Text] [Related]
15. Global glycosphingolipid analysis in urine and plasma of female Fabry disease patients.
Heywood WE; Doykov I; Spiewak J; Hallqvist J; Mills K; Nowak A
Biochim Biophys Acta Mol Basis Dis; 2019 Oct; 1865(10):2726-2735. PubMed ID: 31319156
[TBL] [Abstract][Full Text] [Related]
16. [Contribution of the measurement of globotriaosylceramide in urine to the diagnosis and follow-up of Fabry disease].
Piraud M; Maire I; Froissart R
Rev Med Interne; 2010 Dec; 31 Suppl 2():S270-4. PubMed ID: 21211678
[TBL] [Abstract][Full Text] [Related]
17. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.
Wilcox WR; Oliveira JP; Hopkin RJ; Ortiz A; Banikazemi M; Feldt-Rasmussen U; Sims K; Waldek S; Pastores GM; Lee P; Eng CM; Marodi L; Stanford KE; Breunig F; Wanner C; Warnock DG; Lemay RM; Germain DP;
Mol Genet Metab; 2008 Feb; 93(2):112-28. PubMed ID: 18037317
[TBL] [Abstract][Full Text] [Related]
18. High-Risk Screening for Fabry Disease: Analysis by Tandem Mass Spectrometry of Globotriaosylceramide (Gb
Auray-Blais C; Lavoie P; Boutin M; Abaoui M
Curr Protoc Hum Genet; 2017 Apr; 93():17.26.1-17.26.12. PubMed ID: 28384397
[TBL] [Abstract][Full Text] [Related]
19. Interfering parameters in the determination of urinary globotriaosylceramide (Gb3) in patients with chronic kidney disease.
Gaggl M; Hofer M; Weidner S; Kleinert J; Fauler G; Wallner M; Kotanko P; Paschke E; Sunder-Plassmann G
J Nephrol; 2015 Dec; 28(6):679-89. PubMed ID: 25857295
[TBL] [Abstract][Full Text] [Related]
20. Familial globotriaosylceramide-associated cardiomyopathy mimicking Fabry disease.
Apelland T; Gude E; Strøm EH; Gullestad L; Eiklid KL; Månsson JE; Reinholt FP; Houge G; Dahl CP; Almaas VM; Heiberg A
Heart; 2014 Nov; 100(22):1793-8. PubMed ID: 25031264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
